Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 703-709

  Ke, Hung Lung ^a,b   Chang, Lin Li ^b,c   Yang, Sheau Fang ^a   Lin, Hui Hui ^b,c   Li, Ching Chia ^a,b   Wu, Deng Chyang ^a,b   Wu, Wen Jeng ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Osteopontin; Prognosis; Renal pelvis cancer; Ureter cancer; Urothelial carcinoma

Indexed keywords

OSTEOPONTIN; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; UPPER URINARY TRACT UROTHELIAL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 81055132939     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.10.009     Document Type: Article

References (31)

1. Melamed M.R., Reuter V.E. Pathology and staging of urothelial tumors of the kidney and ureter. Urol Clin North Am 1993, 20:333-347.
2. Chou Y.H., Huang C.H. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 1999, 85:1342-1344.
3. Kang C.H., Yu T.J., Hsieh H.H., et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003, 98:1620-1626.
4. Huben R.P., Mounzer A.M., Murphy G.P. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 1988, 62:2016-2020.
5. Munoz J.J., Ellison L.M. Upper tract urothelial neoplasms: Incidence and survival during the last two decades. J Urol 2000, 164:1523-1525.
6. Li C.C., Chang T.H., Wu W.J., et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 2008, 54:1127-1134.
7. Reitelman C., Sawczuk I.S., Olsson C.A., et al. Prognostic variables in patients with transitional cell carcinoma of the renal pelvis and proximal ureter. J Urol 1987, 138:1144-1145.
8. Rangaswami H., Bulbule A., Kundu G.C. Osteopontin: Role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87.
9. Wai P.Y., Kuo P.C. The role of osteopontin in tumor metastasis. J Surg Res 2004, 121:228-241.
10. Euer N., Schwirzke M., Evtimova V., et al. Identification of genes associated with metastasis of mammary carcinoma in metastatic vs. nonmetastatic cell lines. Anticancer Res 2002, 22:733-740.
11. Rittling S.R., Chambers A.F. Role of osteopontin in tumor progression. Br J Cancer 2004, 90:1877-1881.
12. Coppola D., Szabo M., Boulware D., et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004, 10:184-190.
13. Ang C., Chambers A.F., Tuck A.B., et al. Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 2005, 96:803-805.
14. Epstein J.I., Amin M.B., Reuter V.R., et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22:1435-1448.
15. Greene F.L., Balch C.M., Fleming I.D., et al. AJCC Cancer Staging Manual 2002, Springer-Verlag, New York (NY). 6th ed.
16. Hudkins K.L., Giachelli C.M., Cui Y., et al. Osteopontin expression in fetal and mature human kidney. J Am Soc Nephrol 1999, 10:444-457.
17. Allred D.C., Clark G.M., Elledge R., et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85:200-206.
18. Matsui Y., Utsunomiya N., Ichioka K., et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005, 65:279-283.
19. Yang C.Y., Chiu H.F., Chang C.C., et al. Bladder cancer mortality reduction after installation of a tap-water supply system in an arsenious-endemic area in southwestern Taiwan. Environ Res 2005, 98:127-132.
20. Nortier J.L., Martinez M.C., Schmeiser H.H., et al. Urothelial carcinoma associated with the use of a Chinese herb, Aristolochia fangchi. N Engl J Med 2000, 342:1686-1692.
21. Tan L.B., Chang L.L., Cheng K.I., et al. Transitional cell carcinomas of the renal pelvis and the ureter: Comparative demographic characteristics, pathologic grade and stage, and 5-year survival in a Taiwanese population. BJU Int 2009, 103:312-316.
22. Kohri K., Nomura S., Kitamura Y., et al. Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 1993, 268:15180-15184.
23. Okada H., Moriwaki K., Konishi K., et al. Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am J Kidney Dis 2000, 36:498-506.
24. Hsieh T.J., Chen R., Zhang S.L., et al. Up-regulation of osteopontin gene expression in diabetic rat proximal tubular cells revealed by microarray profiling. Kidney Int 2006, 69:1005-1015.
25. Sodek J., Batista-Da Silva A.P., Zohar R. Osteopontin and mucosal protection. J Dental Res 2006, 85:404-415.
26. Denhardt D.T., Noda M., O'Regan A.W., et al. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061.
27. Arafat H.A., Wein A.J., Chacko S. Osteopontin gene expression and immunolocalization in the rabbit urinary tract. J Urol 2002, 167:746-752.
28. Cho H., Hong S.W., Oh Y.J., et al. Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 2008, 134:909-917.
29. Vaschetto R., Nicola S., Olivieri C., et al. Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med 2008, 34:2176-2184.
30. Chen N.X., O'Neill K.D., Duan D., et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002, 62:1724-1731.
31. Zhao L., Li T., Wang Y., et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 2008, 62:1056-1062.